Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

New research published in the journal Science uncovers how scratching aggravates inflammation and swelling in a mouse model ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Scratching an itchy rash really does make it worse. Now we know why, thanks to new research that uncovers how scratching aggravates inflammation and swelling in a mouse model of a type of eczema ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

Allakos (NASDAQ:ALLK) has dropped ~75% in premarket trading Monday after posting disappointing phase 1 results on AK006 for chronic spontaneous urticaria and deciding to end development. Due to ...

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...

The San Carlos, Calif., clinical-stage biotechnology company, which ended 2024 with roughly $81 million in cash, equivalents and investments, said it expects to use $34 million to $38 million in cash ...

Allakos (ALLK) announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria. In the CSU cohort, 34 adult ...

Exposure to low temperatures for prolonged spells can trigger an array of different health conditions, some of which may be ...